Device Trial Radar · NCT00598663
SWITCH - Sensing With Insulin Pump Therapy to Control HbA1c
Last checked: Nov 20, 2026Latest source record: Sep 16, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
153
Actual
Start
Jan 2008
Primary completion
Jul 2010
Study completion Jul 2010
Sponsor
- Lead sponsor
- Medtronic MiniMed, Inc.Public (MDT)
- Sponsor type
- Industry
- First posted
- Jan 22, 2008
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 6 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate whether the patients with Type 1 diabetes mellitus in sub-optimal glycemic control can achieve better glycemic control by using the Medtronic MiniMed Paradigm® REAL-Time Pump System with continuous glucose monitoring versus the Medtronic MiniMed Paradigm® REAL-Time Pump alone with Self Monitoring Blood Glucose (SMBG).Our null hypothesis is there is a 0% reduction in HbA1c from baseline compared to control group, after 6 months of treatment.
Conditions
- Diabetes Mellitus, Type 1
Interventions
insulin pump with continuous glucose sensing (Paradigm Real-Time Insulin Pump System)Device
6 months of pump plus continuous glucose sensing in conjunction to SMBG
insulin pump and blinded continuous glucose sensing (Paradigm Real-Time insulin pump)Device
insulin pump with smbg to be worn for 6 months. 15 days in each 6 week period blinded continuous glucose sensing will be conducted.
Primary outcomes
What the sponsor says the trial is designed to measure.
- HbA1c at 6 MonthTime frame: 6 months
Locations
8 sites in 7 countries. Site status is shown where the registry gives one.
Hospital Hietzing
Vienna, Austria
Steno Diabetes Center
Copenhagen, Denmark
Glostrup Hospital
Glostrup Municipality, Denmark
5 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.